Chinese patent medicine: five best-selling plant extracts in the domestic market

In many cardiovascular and cerebrovascular system drugs, Chinese patent medicine has become a best-selling product in the domestic market because of its advantages of multiple targets and multiple effects According to the statistics of China Pharmaceutical Business Association, five kinds of plant extract preparations, such as ginkgo injection, Danshen series preparation, Breviscapine injection, puerarin injection and Notoginsenoside, account for more than half of the total sales of all traditional Chinese medicine cardiovascular disease preparations in domestic hospitals Ginkgo biloba preparation is the leading plant medicine in the world Ginaton, a Ginkgo biloba extract, has been widely used in the world since it was developed in 1965 by Dr Weimar Shupei of Germany It is reported that the annual sales volume of Ginkgo biloba preparations in the global market is 5 billion US dollars In China, Zhejiang Kangenbei is the first to develop ginkgo biloba products In 1993, the company was the first one in China to obtain the production number and the commodity name is "Tianbaoning" In clinic, the main application departments of Ginkgo biloba preparation are neurology and health care department, and other departments also use a small amount of Ginkgo biloba preparation Because Ginkgo biloba preparation has a long use time and a wide range of use, it plays an important role in cardiovascular and cerebrovascular auxiliary drugs, especially in the treatment of ischemic encephalopathy, cerebral dysfunction, coronary heart disease and other chronic cardiovascular and cerebrovascular diseases According to the data of 22 sample hospitals in China, Ginkgo biloba preparation has always ranked first in the field of traditional Chinese medicine and cardiovascular and cerebrovascular fields The annual sales volume of Ginkgo biloba preparations in China has grown from 350 million yuan in 2005 to 800 million yuan in 2012, with an overall market growth of 2.3 times in 7 years The compound growth rate from 2005 to 2012 was 12.7%, lower than that of the whole domestic industry In 2007, the amount of Ginkgo biloba preparations used in domestic hospitals reached 740 million yuan, an increase of 44.9% over the same period, a rapid growth; in 2012, the amount of Ginkgo biloba preparations used in domestic hospitals reached 800 million yuan, a decrease of 2.1% over the same period The sales volume of the product reached a peak of 820 million yuan in 2011 From the perspective of sales trend from 2005 to 2012, the market is in a period of high-speed growth from 2005 to 2008, but in a steady downward trend from 2008 to 2012 According to the statistics of PDB database, Ginkgo biloba preparation ranked 11th among the top 100 drugs in the sample hospitals in 2011, and dropped to 21st in 2012 From 2005 to 2006, the imported Ginkgo biloba preparations accounted for the main share in the domestic market, especially in the injection area, with sales leading all the way From 2007 to 2012, domestic enterprises increased their development efforts and gradually reversed the situation that foreign enterprises dominated the market and domestic preparations dominated the market According to the data of 22 sample hospitals in China, in 2012, there were more than 50 Ginkgo biloba preparation manufacturers, with the sales volume of the top 10 enterprises accounting for 93.0%, and the market was relatively concentrated The top five enterprises are: Heilongjiang Treasure Island Pharmaceutical Co., Ltd., with sales of 138 million yuan; Hebei Shijiazhuang Shenwei Pharmaceutical Co., Ltd., with sales of 135 million yuan; Weima Shupei doctor Pharmaceutical Co., Ltd (Germany), with sales of 108 million yuan; Beijing Shuanghe Pharmaceutical Co., Ltd., with sales of 104 million yuan; Shanxi Sanjiu Wanrong Pharmaceutical Co., Ltd., with sales of 77.96 million yuan The market share was 17.1%, 16.9%, 13.5%, 13.0% and 9.7% respectively, and the growth rate in 2012 was 29.1%, - 7.0%, 4.3%, 5.4% and 20.7% compared with the same period in 2011 The market share of the top five enterprises is relatively balanced In terms of the growth rate in the same period, the domestic enterprises Heilongjiang Zhenbaodao pharmaceutical and Shanxi Sanjiu Wanrong pharmaceutical industry have both increased by more than 20% compared with the same period, with a rapid growth rate It is worth mentioning that Dr Weimar Shupei pharmaceutical factory (Germany), ranking the third, produces Ginkgo biloba preparations in three dosage forms, i.e injection, tablet and drop (ginado), with sales of 69.62 million yuan, 34.47 million yuan and 36.72 million yuan respectively After more than 10 years of development, the domestic enterprises of Ginkgo biloba preparation occupy the leading position, and are in the era of competing According to statistics, as of November 2013, the State Food and drug administration has issued more than 140 approval documents for the production of Ginkgo biloba extract chemicals and composite preparations, with nearly 100 manufacturers With the in-depth study of Ginkgo biloba extract in China, Ginkgo biloba extract approved for marketing in China includes injection, tablet, drop pill, capsule, granule and oral liquid According to the data of 22 sample hospitals in China, in 2012, the sales volume of injections was 530 million yuan, and the sales volume of tablets, pills, capsules and other oral preparations totaled 270 million yuan The sales volume of injections and oral preparations accounted for 66.2% and 33.8% respectively, with injections playing a leading role The sales volume of Ginkgo biloba injection increased from 220 million yuan in 2005 to 530 million yuan in 2012, with an overall market growth of 2.4 times in 7 years and a compound growth rate of 13.5% The sales volume of oral preparations increased from 130 million yuan in 2005 to 270 million yuan in 2012, with the overall market growth of 2.1 times and the compound growth rate of 11.1% From the perspective of injection sales trend from 2005 to 2012, the market is in a period of high-speed growth from 2005 to 2008, and the market has declined steadily from 2008 to 2012 From the perspective of the sales trend of oral preparations in 2005-2012, the market in 2005-2012 is in a stable trend, with little change in the trend of oral tablets, pills, capsules, etc It can be seen that the marketing trend of injection determines the market trend of Ginkgo biloba preparation In recent years, the competition among the brands of Ginkgo biloba preparation market is increasingly fierce With the emergence of new products in the market, the growth of the whole Ginkgo biloba preparation market tends to slow down With the continuous expansion of domestic cardiovascular and cerebrovascular drug capacity and the sinking of terminal market development, the high-end market of Ginkgo biloba injection has potential to be explored in the future Oral preparations have good opportunities to expand in the third terminal and OTC market.